Emory University - Pharmaceuticals & Healthcare - Deals and Alliances Profile
September 2018
74
About the Report
About the Report
Summary
Emory University (Emory) is an educational service provider that offers academic degrees and programs through its arts colleges and graduate and professional schools. The university offers degree programs in the areas of business, law, medicine, nursing, public health, theology, and online courses and programs. It operates new faculties across all the schools which include AIDS, Alzheimer's, cancer, cardiology, diversity, economics and finance, global health, health, infectious diseases, influenza, neuroscience, pediatrics, politics, psychiatry, psychology, public health, religion and ethics, research, science and surgery. The university also operates research facilities. Emory is headquartered in Atlanta, Georgia, the US.
Emory University-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.
GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.
Scope
- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.
- Business Description-A brief description of the company's operations.
- Key Employees-A list of the key executives of the company.
- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors-A list of the key competitors of the company.
- Key Recent Developments-A brief on recent news about the company.
Reasons to buy
Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements
- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.
Understand the company's business segments' expansion / divestiture strategy
- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.
Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.
Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.
- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.
Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.
Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.
Note*: Some sections may be missing if data is unavailable for the company.
Products
Products
Emory University, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.
Table of Contents
Table of Contents
Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Emory University, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Emory University, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Emory University, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Emory University, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Emory University, Medical Devices Deals, 2012 to YTD 2018 10
Emory University, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11
Emory University, Pharmaceuticals & Healthcare, Deal Details 13
Partnerships 13
Empire Genomics Enters Into Licensing Agreement With Emory University For Genomic Biomarkers 13
Celltrion Enters into Development Agreement with Emory University 14
Geovax Labs and Emory University Enter into Partnership 15
Applied Therapeutics Enters into Agreement with Emory University 16
Moleculin Biotech Enters into Agreement with Emory University 17
Vaccinex Enters into Agreement with Emory University 18
AKESOgen and Emory University School of Medicine Enter into Partnership 19
Medibio Enters into Agreement with Emory University 20
Defense Threat Reduction Agency Enters into Contract with Emory University 21
Spotlight Innovation Enters into Research Agreement with Emory University 22
Emory University And Children's Hospital of Philadelphia Enter Into Co-Development Agreement With Harvard University 23
NextBio Enters Into Research Agreement With Emory University And Aflac Cancer Center For Medulloblastoma Biomarkers 24
Emory University Enters Into Joint Venture With UniQuest To Form Que Oncology 25
NextBio Enters Into Agreement With Winship Cancer Institute of Emory University For Myeloma Biomarkers 26
Bristol-Myers Squibb Enters Into Co-Development Agreement With Emory University 27
Licensing Agreements 28
Cocrystal Pharma Enters into Licensing Agreement with Duke University and Emory University 28
Meissa Vaccines Enters into Agreement with Emory University for Rhinovirus Vaccine 30
Meissa Vaccines Enters into Agreement with Emory University for RSV Vaccine Technologies 31
Incysus Enters into Licensing Agreement with Emory University, Children's Hospital of Atlanta and University of Alabama at Birmingham 32
Cambium Medical Technologies Enters into Licensing Agreement with Emory University 33
Primatope Therapeutics Enters into Licensing Agreement with Emory University 34
Cocrystal Pharma Enters into Licensing Agreement with Emory University 35
Clearside Biomedical Enters into Licensing Agreement with Emory University and GTRC 36
Carrick Therapeutics Enters into Licensing Agreement with Emory University 37
Genomind Enters Into Licensing Agreement With Emory University 38
RayBiotech Enters Into Licensing Agreement With Emory University 39
Metaclipse Therapeutics Enters Into Option For License Agreement With Emory University 40
Acquisition 41
Eurofins Scientific Acquires 75% Stake in Emory Genetics Lab for USD40 Million 41
Emory University-Key Competitors 42
Emory University-Key Employees 43
Emory University-Locations And Subsidiaries 45
Head Office 45
Other Locations & Subsidiaries 45
Joint Venture 45
Recent Developments 47
Government and Public Interest 47
Sep 24, 2018: FDA awards 12 grants to fund new clinical trials to advance the development of medical products for the treatment of rare diseases 47
Sep 18, 2018: Grant supports identifying leukemia, Down syndrome link 49
Sep 07, 2018: NIH USD 3 million grant will enable Emory, Georgia Tech researchers to tackle sickle cell disease with new technologies 50
Sep 04, 2018: UIC to lead study of negative pressure wound therapy in obese and diabetic patients 51
Aug 22, 2018: Looking ahead to new opioid treatments 52
Jul 24, 2018: International panel releases new guidelines for HIV treatment and prevention 53
Jul 18, 2018: St. Baldrick's foundation announces USD 19.1 million in grants to fund lifesaving childhood cancer research 54
Jul 03, 2018: Study confirms real-world impact of lifestyle modification on diabetes prevention 55
Jun 28, 2018: Complexity of NMDA Receptor Drug Discovery Target Revealed 56
Jun 08, 2018: Antibiotic resistant bacteria found in the U.S. presents a triple threat 57
May 10, 2018: New Grants Totaling USD 2.6 Million Fund Work to Reduce Immunotherapy Side Effects 58
May 08, 2018: Enzyme Blocker Stops Growth of Deadly Brain Tumor 59
Apr 16, 2018: Relypsa Funds Three Innovative Research Projects on Hyperkalemia and Associated Disorders 60
Jan 03, 2018: Primate genomics study reveals clues into AIDS resistance 61
Sep 25, 2017: Georgia Clinical Translational Science Alliance receives USD 51 million NIH state-wide grant 62
Sep 07, 2017: NIH awards nearly USD 100 million for Autism Centers of Excellence program 64
Aug 30, 2017: Alzheimer's Foundation of America awards grant to Emory's Alzheimer's Disease Research Center 66
Aug 29, 2017: Morehouse School of Medicine Joins the NIH All of Us Research Consortium 67
Aug 29, 2017: NIH's All of Us Research Program expands national network of medical centers 68
Aug 25, 2017: Study identifies genes linked to better immune response to flu vaccine 69
Aug 24, 2017: Lower blood pressure targets for older adults may offer cognitive benefits, study suggests 70
Aug 23, 2017: Cancer drug discovery: Targeting DNA repair 71
Jan 20, 2017: South African Study Provides Compelling New Evidence on Role of Person-to Person Transmission in Drug-Resistant TB Epidemics 72
Product News 73
Jan 26, 2018: Tactic for controlling motor symptoms of advanced Parkinson's 73
Appendix 74
Methodology 74
About GlobalData 74
Contact Us 74
Disclaimer 74
List of Figure
List of Figures
Emory University, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Emory University, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Emory University, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Emory University, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Emory University, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Emory University, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7
Emory University, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Emory University, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Emory University, Medical Devices Deals, 2012 to YTD 2018 10
List of Table
List of Tables
Emory University, Pharmaceuticals & Healthcare, Key Facts 2
Emory University, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Emory University, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Emory University, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Emory University, Deals By Therapy Area, 2012 to YTD 2018 9
Emory University, Medical Devices Deals, 2012 to YTD 2018 10
Emory University, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11
Empire Genomics Enters Into Licensing Agreement With Emory University For Genomic Biomarkers 13
Celltrion Enters into Development Agreement with Emory University 14
Geovax Labs and Emory University Enter into Partnership 15
Applied Therapeutics Enters into Agreement with Emory University 16
Moleculin Biotech Enters into Agreement with Emory University 17
Vaccinex Enters into Agreement with Emory University 18
AKESOgen and Emory University School of Medicine Enter into Partnership 19
Medibio Enters into Agreement with Emory University 20
Defense Threat Reduction Agency Enters into Contract with Emory University 21
Spotlight Innovation Enters into Research Agreement with Emory University 22
Emory University And Children's Hospital of Philadelphia Enter Into Co-Development Agreement With Harvard University 23
NextBio Enters Into Research Agreement With Emory University And Aflac Cancer Center For Medulloblastoma Biomarkers 24
Emory University Enters Into Joint Venture With UniQuest To Form Que Oncology 25
NextBio Enters Into Agreement With Winship Cancer Institute of Emory University For Myeloma Biomarkers 26
Bristol-Myers Squibb Enters Into Co-Development Agreement With Emory University 27
Cocrystal Pharma Enters into Licensing Agreement with Duke University and Emory University 28
Meissa Vaccines Enters into Agreement with Emory University for Rhinovirus Vaccine 30
Meissa Vaccines Enters into Agreement with Emory University for RSV Vaccine Technologies 31
Incysus Enters into Licensing Agreement with Emory University, Children's Hospital of Atlanta and University of Alabama at Birmingham 32
Cambium Medical Technologies Enters into Licensing Agreement with Emory University 33
Primatope Therapeutics Enters into Licensing Agreement with Emory University 34
Cocrystal Pharma Enters into Licensing Agreement with Emory University 35
Clearside Biomedical Enters into Licensing Agreement with Emory University and GTRC 36
Carrick Therapeutics Enters into Licensing Agreement with Emory University 37
Genomind Enters Into Licensing Agreement With Emory University 38
RayBiotech Enters Into Licensing Agreement With Emory University 39
Metaclipse Therapeutics Enters Into Option For License Agreement With Emory University 40
Eurofins Scientific Acquires 75% Stake in Emory Genetics Lab for USD40 Million 41
Emory University, Key Competitors 42
Emory University, Key Employees 43
Emory University, Subsidiaries 45
Emory University, Joint Venture 45
Why Buy From US?
What makes us stand out is that our consultants follows Robust, Refine and Result (RRR) methodology. i.e. Robust for clear definitions, approaches and sanity checking, Refine for differentiating respondents facts and opinions and Result for presenting data with story
We have set a benchmark in the industry by offering our clients with syndicated and customized market research reports featuring coverage of entire market as well as meticulous research and analyst insights.
While we don't replace traditional research, we flip the method upside down. Our dual approach of Top Bottom & Bottom Top ensures quality deliverable by not just verifying company fundamentals but also looking at the sector and macroeconomic factors.
With one step in the future, our research team constantly tries to show you the bigger picture. We help with some of the tough questions you may encounter along the way: How is the industry positioned? Best marketing channel? KPI's of competitors? By aligning every element, we help maximize success.
Our report gives you instant access to the answers and sources that other companies might choose to hide. We elaborate each steps of research methodology we have used and showcase you the sample size to earn your trust.
If you need any support, we are here! We pride ourselves on universe strength, data quality, and quick, friendly, and professional service.